E6
binds to p53, a major tumor suppressor in the cell that normally activates
transcription of p21, an inhibitor of kinases that promote mitosis.
http://www.telemedicine.org/warts/cutmanhpv.htm
The E6 oncoproteins in HPV have been shown to be one of the main players in the progression to cervical cancer. E6 in HPVs that are at high risk of causing cancer can complex with p53, which is an important tumor suppressor that plays a role in directing the cellular response to genotoxic and cytotoxic stresses that threaten genomic stability. It functions as a sequence specific transcription activator that is necessary to regulate cell growth as well as tumor growth suppression. The p53 protein suppresses cell growth by transcriptionally activating p21, which inhibits the cell-cycle kinases critical for G1 progression and cell growth.
HPV E6 has also been shown to induce degradation
of p53 through ubiquitin-dependent proteolysis. E6 forms a complex with the
cellular ubiquitin protein ligase E6-AP, which is then able to bind and
ubiquinate p53.
p53 usually acts to arrest G1 growth or to
induce apoptosis in the cell to allow the host DNA to be repaired or for the
cell to be eliminated if the DNA is irreparable. E6-expressing cells do not
manifest a p53-mediated cellular response to DNA damage, which leads to genomic
instability. E6 can also activate telomerase independent of p53, leading to
immortalization of the infected cell. There is also evidence that E6 can induce
abnormal centrosome duplication, leading to genomic instability and aneuploidy.
E2F
is a cell-cycle activator that is regulated by the binding of pRB, a cellular
tumor suppressor. HPV protein E7 can bind to pRB, rendering it unable to bind
and regulate E2F, which then can freely activate the cell cycle to progress
uncontrollably.
http://www.telemedicine.org/warts/cutmanhpv.htm
E7 can transactivate the E2 promoter, inducing
DNA synthesis in quiescent cells. E2 normally binds to retinoblastoma tumor
suppressor pRB. Its phosphorylation state is regulated through the cell cycle
such that in normal conditions it is hypophosphorylated in G0 and G1 phase and
is phosphorylated during S, G2, and M phase. pRB becomes phosphorylated by
cyclin-dependent kinases at the G1 to S phase and remains phosphorylated until
the M phase. The hypophosphorylated form is its active form in which it can
inhibit cell-cycle progression. E7 binds to the hypophosphorylated form of pRB,
functionally inactivating it and thus permiting cell-cycle progression of the
cell into S phase. Thus, E7 is able to induce DNA synthesis and cellular
proliferation.
pRB regulates members of the E2F family
transcription factors. When E2F
are bound to the hypophosphorylated form of pRB, E2F functions as a
transcriptional repressor. When pRB is phosphorylated by cyclin-dependent
kinase complexes, the pRB-E2F complex dissociates and E2F is free to act as a
transcriptional activator. E2F acts as both an activator (G1 through S) and a
repressor (M through G1) at different points in the cell cycle. When E7 binds
pRB, pRB cannot bind to E2F and thus E2F freely activates the cell cycle.
It is known that viral E2 regulates the activity
of E6 and E7, which are implicated in tumorigenesis. It is thought that in
cervical keratinocytes that have been infected with HPV for a length of time,
certain events occur in which the viral genome is integrated into the host genome,
causing a deletion in the 3' region of the viral genome. This deletion results
in the loss of the E2 region, leading to a loss of regulation of E7
transcription. Thus, after this
integration event, E7 can be transcribed at higher rates and the risk for
cancer increases tremendously.